Sanofi’s specialty care global business unit -- Sanofi Genzyme has launched its multiple sclerosis treatment drug ‘Aubagio’ in India. The drug offers patients diagnosed with multiple sclerosis the efficacy and convenience of once-a-day oral treatment.
Aubagio is a differentiated disease modifying therapy that blocks the enzyme involved in multiplication of overactive immune cells.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.
